Optimising Anticoagulation For Stroke Prevention in Patients with NVAF – Part 2
Thursday, 17 June, 2021 20:00-21:00
Part 2: Switching from Warfarin to a NOAC
An interactive discussion on the latest recommendations for practical management of anticoagulation in patients with NVAF
Speaker: Lynne Garforth
- Case study: following a patient who is switched from warfarin to apixaban
- Key changes in the latest 2021 NICE guidance
- The use of ORBIT as a bleeding risk score tool
- DOACs as first-line treatment for newly diagnosed patients with NVAF
To discuss the option of switching to a DOAC in patients with NVAF who are already taking a VKA and are stable.
Book your place here.